Phase 3 randomized double-blind study evaluating selinexor, an XPO1 inhibitor, plus ruxolitinib in jaki-naïve myelofibrosis: Study rationale and preliminary patient characteristics

Authors

Institutions

Publication Details

Journal
Blood
Published
2025-11-03
DOI
https://doi.org/10.1182/blood-2025-7353
Primary Topic
Myeloproliferative Neoplasms: Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Phase 3 randomized double-blind study evaluating selinexor, an XPO1 inhibitor, plus ruxolitinib in jaki-naïve myelofibrosis: Study rationale and preliminary patient characteristics

Hsin‐An Hou, Antonín Hluší, Michael L. Loschi, Prithviraj Bose et al.
Blood
Myeloproliferative Neoplasms: Diagnosis and Treatment
article

Phase 3 randomized double-blind study evaluating selinexor, an XPO1 inhibitor, plus ruxolitinib in jaki-naïve myelofibrosis: Study rationale and preliminary patient characteristics

Hsin‐An Hou, Antonín Hluší, Michael L. Loschi, Prithviraj Bose, Pietro Taverna, Darko Miljkovic, Antonio Galleu, Jennifer O Sullivan, Valentín García‐Gutiérrez, Pankit J. Vachhani, Srinivas K. Tantravahi, Andrea Patriarca, Yi Chai, Haifa Kathrin Al‐Ali, Жанет Грудева-Попова, Sebastian Grosicki, Haris Ali, John O Mascarenhas, Emanuele Ammatuna, Raajit K. Rampal, Laura Urian, Von Potter, Sung Eun Lee
article en

Abstract

No abstract available for this paper.
BloodVol. 146(Supplement 1)
City Of Hope National Medical Center (US), University Medical Center Groningen (NL), Memorial Sloan Kettering Cancer Center (US), The University of Texas MD Anderson Cancer Center (US), Medical University of Silesia (PL), Guy's and St Thomas' NHS Foundation Trust (GB), Iuliu Hațieganu University of Medicine and Pharmacy (RO), Zurich Insurance Group (Switzerland) (CH), Medical University Plovdiv (BG), Huntsman Cancer Institute (US), Centre Hospitalier Universitaire de Nice (FR), University of Alabama at Birmingham (US), University Hospital Olomouc (CZ), Ospedale di Santo Spirito (IT), Thomas Foundation (AU), Menarini Group (Italy) (IT), City of Hope (US), Instituto Ramón y Cajal de Investigación Sanitaria (ES), National Taiwan University Hospital (TW), St Mary's Hospital (GB), Agricultural University Plovdiv (BG), St. Paul's Hospital (KR), University Hospital in Halle (DE), Karyopharm Therapeutics (United States) (US), The Catholic University of Korea Seoul St. Mary's Hospital (KR), Plovdiv University (BG), Palacký University Olomouc (CZ), University of Silesia in Katowice (PL), Icahn School of Medicine at Mount Sinai (US)
Openalex Percentile: Top 43%
Myeloproliferative Neoplasms: Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.